ZNTL
Zentalis Pharmaceuticals LlcNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$289.02M
P/E Ratio
—
EPS
$-1.74
Beta
2.00
52W High
$6.95
52W Low
$1.13
50-Day MA
$3.67
200-Day MA
$2.31
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Zentalis Pharmaceuticals Llc
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapies for the treatment of various cancers. The company is headquartered in New York, New York.
Fundamentals
| Revenue (TTM) | $26.86M |
| Gross Profit (TTM) | $26.86M |
| EBITDA | $-140.28M |
| Operating Margin | 0.00% |
| Return on Equity | -51.90% |
| Return on Assets | -27.70% |
| Revenue/Share (TTM) | $0.37 |
| Book Value | $3.13 |
| Price-to-Book | 1.58 |
| Price-to-Sales (TTM) | 7.13 |
| EV/Revenue | 0.385 |
| EV/EBITDA | -2.31 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $71.19M |
| Float | $48.84M |
| % Insiders | 22.44% |
| % Institutions | 62.06% |
Historical Volatility
HV 10-Day
148.63%
HV 20-Day
112.70%
HV 30-Day
123.69%
HV 60-Day
112.90%
HV Rank
86.9%
Volatility is currently expanding
Analyst Ratings
Consensus ($6.50 target)
4
Buy5
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026